Shares of AbbVie (ABBV) are under pressure on Wednesday after the Food and Drug Administration issued a safety update on JAK inhibitors and announced it is strengthening the black box warning for the company’s Rinvoq as the agency concluded it couldn’t rule out Xeljanz-like safety concerns. Commenting on the… To see the rest of the story go to thefly.com. (See Story Here):(https://www.thefly.com/permalinks/entry.php/id3366068/-Analysts-remain-bullish-on-AbbVie-despite-FDA-warning-on-arthritis-drug)
previous post